Company News

PBR reports that US-based novel drug developer Isis Pharmaceuticals (NASDAQ:ISIS) has received a payment of $6m from AstraZeneca (LSE:AZN) to continue their contract research agreement to discover and develop new antisense therapeutics to treat cancer.

PBR reports that US-based novel drug developer Isis Pharmaceuticals (NASDAQ:ISIS) has received a payment of $6m from AstraZeneca (LSE:AZN) to continue their contract research agreement to discover and develop new antisense therapeutics to treat cancer.

As quoted in the market news:

Commenting on the research partnership, Isis Pharmaceuticals chief operating officer Lynne Parshall said, “Our oncology franchise consists of five antisense drugs in development to treat patients with a variety of cancers.”

Click here for the full news report by PBR

Featured

MARKETS

Markets
TSX20286.20+88.59
TSXV700.66-1.43
DOW31928.62+48.38
S&P 5003941.48-32.27
NASD11264.45-270.83
ASX7128.80-20.10

COMMODITIES

Commodities
Gold1862.82-4.47
Silver22.06-0.07
Copper4.30-0.01
Palladium2023.62+26.62
Platinum956.47+0.47
Oil111.12+1.35
Heating Oil3.69+0.04
Natural Gas8.82+0.03

DOWNLOAD FREE REPORTS

×